Systemic therapy for stage IV melanoma that is BRAF (V600E) mutation positive is rapidly emerging and combination therapy with a BRAF and MEK inhibitor show particular promise [NCT01584648] with the median progression free survival reported as 9.4 months in patients with combination therapy compared to 5.8 months in those receiving dabrafenib monotherapy [61]. This evidence concerns the gene BRAF and melanoma.